|
1) Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis; emerging applications. J Am Coll Cardiol. 2006; 47: 1328-38
|
|
|
|
2) Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov. 2008; 7: 517-29
|
|
|
|
|
|
3) Langer HF, Haubner R, Pichler BJ, et al. Radionuclide imaging. J Am Coll Cardiol. 2008; 52: 1-12
|
|
|
|
|
|
4) Sadeghi MM, Glover DK, Lanza GM, et al. Imaging atherosclerosis and vulnerable plaque. J Nucl Med. 2010; 51: 51-65S
|
|
|
|
|
|
5) Elkhawad M, Rudd JH. Radiotracer imaging of atherosclerotic plaque biology. Cardiol Clin. 2009; 27: 345-54
|
|
|
|
|
|
6) Fox JJ, Strauss HW. One step closer to imaging vulnerable plaque in the coronary arteries. J Nucl Med. 2009; 50: 497-500
|
|
|
|
|
|
7) Ogawa M, Ishino S, Mukai T, et al. 18F-FDG accumulation in atherosclerotic plaques: immuno-histochemical and PET imaging study. J Nucl Med. 2004; 45: 1245-50
|
|
|
|
|
|
8) Rudd JHF, Myers KS, Bansilal S, et al. 18Fluoro-deoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible. J Am Coll Cardiol. 2007; 50: 892-6
|
|
|
|
|
|
9) Bural GG, Torigian DA, Chamroonrat W, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008; 35: 562-9
|
|
|
|
|
|
10) Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009; 50: 563-8
|
|
|
|
|
|
11) Ogawa M, Magata Y, Kato T, et al. Application of [18F]FDG-PET for monitoring the therapeutic effect of anti-inflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med. 2006; 48: 1822-7
|
|
|
|
|
|
12) Wu YW, Kao HL, Chen MF, et al. Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J Nucl Med. 2007; 48: 227-33
|
|
|
|
|
|
13) Tahara N, Kai H, Yamagishi S, et al. Vascular inflammation evaluated by [18F]-fluorodeoxy-glucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007; 49: 1533-9
|
|
|
|
|
|
14) Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006; 48: 1825-31
|
|
|
|
|
|
15) Lee SJ, On YK, Lee EJ, et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. 2008; 49: 1277-82
|
|
|
|
|
|
16) Matter CM, Wyss MT, Meier P, et al. 18F-Choline images murine atherosclerotic plaques ex vivo. Arterioacler Thromb Vasc Biol. 2006; 26; 584-9
|
|
|
|
|
|
17) Ishino S, Mukai T, Kume N, et al. Lectin-like oxidized LDL receptor-1(LOX-1)expression is associated with atherosclerotic plaque instability-analysis in hypercholesterolemic rabbits. Atherosclerosis. 2007; 195: 48-56
|
|
|
|
|
|
18) Ishino S, Mukai T, Kuge Y, et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1(LOX-1)with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. J Nucl Med. 2008; 49: 1677-85
|
|
|
|
|
|
19) Li D, Patel A, Klibanov A, et al. Molecular imaging of atherosclerotic plaques targeted on oxidized LDL receptor LOX-1 using SPECT/CT and magnetic resonance [abstract]. J Nucl Med. 2009; 50: 657
|
|
|
|
|
|
20) Sarai M, Hartung D, Petrov A, et al. Broad and specific caspase inhibitor-induced acute repression of apoptosis in atherosclerotic lesions evaluated by radiolabeled annexin A5 imaging. J Am Coll Cardiol. 2007; 50: 2305-12
|
|
|
|
|
|
21) Laufer EM, Winkens MHM, Narula J, et al. Molecular imaging of macrophage cell death for the assessment of plaque vulnerability. Arteroscler Thromb Vasc Biol. 2009; 29: 1031-8
|
|
|
|
|
|
22) Nguyen QD, Smith G, Glaser M, et al. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A. 2009; 106: 16375-80
|
|
|
|
|
|
23) Ohshima S, Petrov A, Fujimoto S, et al. Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein E or low-density-lipoprotein receptor. J Nucl Med. 2009; 50: 612-7
|
|
|
|
|
|
24) Zhang J, Nie L, Razavian M, et al. Molecular imaging of activated matrix metalloproteinase activity in the arterial wall in vivo. Circulation. 2008; 118: 1953-60
|
|
|
|
|
|
25) Fujimoto S, Hartung D, Edward DS, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol. 2008; 52: 1847-57
|
|
|
|
|
|
26) Tekabe Y, Qing L, Luma J, et al. Noninvasive monitoring the biology of atherosclerotic plaque development with radiolabeled annexin V and matrix metalloproteinase inhibitor in spontaneous atherosclerotic mice. Circulation. 2009; 120 Suppl: S365-6
|
|
|
|
|
|
27) Kuge Y, Takai N, Ishino S, et al. Distribution profiles of membrane Type-1 Matrix Metalloproteinase(MT1-MMP), Matrix Metalloproteinase-2(MMP-2)and cyclooxygenase-2(COX-2)in rabbit atherosclerosis: comparison with plaque instability analysis. Biol Pharm Bull. 2007; 30: 1634-40
|
|
|
|
|
28) Annovazz A, Bonanno E, Arca M, et al. 99mTc-interleukin-2 scntigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2006; 33: 117-26
|
|
|
|
|
|
29) Hartung D, Petrov A, Haider N, et al. Radio-labeled monocyte chemotactic protein 1 for the detection of inflammation in experimental atherosclerosis. J Nucl Med. 2007; 48: 1816-21
|
|
|
|
|
|
30) van den Borne SWM, Isobe S, Verjans JW, et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol. 2008; 52: 2017-28
|
|
|
|
|
|
31) Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008; 117: 379-87
|
|
|
|
|
|
32) Cunningham CH, Arai T, Yang P, et al. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med. 2005; 53: 999-1005
|
|
|
|
|
|
33) Dharmakumar R, Koktzoglou I, Li D. Generating positive contrast from off-resonant spins with steady-state free precession magnetic resonance imaging: theory and proof-of-principle experiments. Phys Med Biol. 2006; 51: 4201-15
|
|
|
|
|
|
34) Mani V, Briley-Saebo KC, Itskovich VV, Set al. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1. 5T and 3T. Magn Reson Med. 2006; 55: 126-35
|
|
|
|
|
|
35) Zurkiya O, Hu X. Off-resonance saturation as a means of generating contrast with superparamagnetic nanoparticles. Magn Reson Med. 2006; 56: 726-32
|
|
|
|
|
|
36) Stuber M, Gilson WD, Schar M, et al. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn Reson Med. 2007; 58: 1072-7
|
|
|
|
|
|
37) Korosoglou G, Tang L, Kedziorek D, et al. Positive contrast MR-lymphography using inversion recovery with ON-resonant water suppression (IRON). J Magn Reson Imaging. 2008; 27: 1175-80
|
|
|
|
|
|
38) Korosoglou G, Weiss RG, Kedziorek DA, et al. Noninvasive detection of macrophage-rich athero-sclerotic plaque in hyperlipidemic rabbits using “positive contrast" magnetic resonance imaging. J Am Coll Cardiol. 2008; 52: 483-91
|
|
|
|
|
|
39) Winter P, Caruthers S, Zhang H, et al. Anti-angiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. J Am Coll Cardiol Imaging. 2008; 1: 624-34
|
|
|
|
|
|
40) Cyrus T, Zhang H, Allen JS, et al. Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol. 2008; 28: 820-6
|
|
|
|
|